These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2227073)

  • 41. [Determination of the anti-anoxia capacity of drugs].
    Truchaud M
    Sem Hop Ther; 1977 Nov; 53(9):425-9. PubMed ID: 341317
    [No Abstract]   [Full Text] [Related]  

  • 42. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 44. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of cyclandelate on in vitro red blood cell deformability.
    Hall DW; van den Hoven WE
    Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigation on spasmolytics. VII. The metabolism of 3,5,5-trimethylcyclohexylmandelate (cyclandelate). II.
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jun; 12():632-5. PubMed ID: 13890671
    [No Abstract]   [Full Text] [Related]  

  • 48. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

  • 49. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 50. [Controlled clinical study of Novodil in the treatment of senile macular lesions].
    Delafoulhouje C; Dalens H; Solé P
    Bull Soc Ophtalmol Fr; 1985 Oct; 85(10):1065-7. PubMed ID: 3915881
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparative effect of cyclandelate and papaverine on the cerebral circulation of the rabbit].
    Dumery JP
    Nouv Presse Med; 1976 Oct; 5(32):2081. PubMed ID: 980735
    [No Abstract]   [Full Text] [Related]  

  • 52. Investigation into 3.5.5-trimethylcyclohexyl mandelate (cyclospasmol).
    EIJKEL G; ERNSTING MJ; REKKER RF; NAUTA WT
    Pharm Weekbl; 1956 Feb; 91(3):81-90. PubMed ID: 13310218
    [No Abstract]   [Full Text] [Related]  

  • 53. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency.
    Smith WL; Lowrey JB; Davis JA
    Curr Ther Res Clin Exp; 1968 Dec; 10(12):613-8. PubMed ID: 4972756
    [No Abstract]   [Full Text] [Related]  

  • 54. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 55. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate].
    Dimpfel W; Schober F; Wedekind W; Kleinbloesem C; Coors C
    Arzneimittelforschung; 1994 Sep; 44(9):999-1004. PubMed ID: 7986255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative gas chromatographic mass spectrometric determination of mandelic acid in blood plasma. Comparison of deuterated and homologous internal standards.
    Luthe H; Ludwig-Köhn H; Langenbeck U
    Biomed Mass Spectrom; 1983 Mar; 10(3):183-6. PubMed ID: 6850070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 60. [Effect of the mandelic ester of 3,5,5-trimethyl-cyclohexanol (Cyclospasmol) on blood flow potentials in peripheral obstructive arteriopathies].
    Russo A; Azzolina P; Biondi M; Montemagno S; Giovinetto A
    Minerva Med; 1969 Aug; 60(69):3110-6. PubMed ID: 5824709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.